Patent · US Expired

Mutant cell lines and methods for producing enhanced levels of recombinant proteins

US6762038B1 · kind B1 · utility

0Cited by
4References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 9, 1999
Grant dateJul 13, 2004
Priority date
Expiry dateSep 9, 2019

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2710/10322
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Mammalian somatic cells having a homozygous disruption in the gene which encodes the endonbonuclease RNase L and a homyzgous disruption in the gene which encodes the double-stranded RNA dependent kinase PKR are provided. Methods for producing enhanced levels of recombinant proteins in mammalian cell systems are also provided. In one aspect the method employs cells having a homozygous disruption in the RNase L gene and a homozygous disruption in the PKR gene and comprises transfecting the cells with a nucleic acid, or polynucleotide, encoding a desired, exogenous protein; expressing the exogenous protein in the cell; and isolating the exogenous protein from the transfected cells. In another aspect the method employs RNase L null cells transfected with a nucleic acid encoding a desired, exogenous protein. In another aspect the methods employ mutant cells hating a homozygous disruption in the PKR gene, i.e. PKR null cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.